Quick answer
Dr. Natalie Hughes is a Early Career Regulatory Writer for United States & Americas pharmaceutical intelligence editor on NovaPharmaNews, with 33 published articles covering FDA regulatory actions, clinical development, and market-moving news. Dr. Natalie Hughes tracks fast-moving FDA guidance, label changes, and review trends impacting small and mid-cap biotech. She brings 4 years of focused reporting with a strong emphasis on operational takeaways for lean teams.
About Dr. Natalie Hughes
Dr. Natalie Hughes tracks fast-moving FDA guidance, label changes, and review trends impacting small and mid-cap biotech. She brings 4 years of focused reporting with a strong emphasis on operational takeaways for lean teams.
Coverage focus
Topics and beats Dr. covers across United States & Americas.
Explore related intelligence
Entity directories linked from this author's coverage.
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways
Articles by Dr. Natalie Hughes
Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment
Neurocrine Biosciences initiates first-in-human Phase 1 trial for NBIP-2118, a novel CRF2 receptor agonist targeting obesity through non-incretin mechanisms.
Opus Genetics' OPGx-LCA5 Gene Therapy Accepted Into FDA's Rare Disease Evidence Program
Opus Genetics announces FDA acceptance of OPGx-LCA5 gene therapy into RDEP program, advancing treatment for inherited retinal disease LCA5.
InspireMD Receives FDA Approval for SwitchGuard Neuro Protection System CGUARDIANS III Pivotal Trial
InspireMD secures FDA IDE approval for CGUARDIANS III pivotal study of SwitchGuard Neuro Protection System, advancing stroke prevention technology development.
Akebia Therapeutics Vadadustat Shows Significant Mortality Reduction in New Kidney Disease Analysis
Akebia Therapeutics announces Vadadustat post-hoc analysis published in JASN shows statistically significant reduction in mortality and hospitalization for kidney disease patients.
Spinogenix Tazbentetol Shows Neuroprotective Effects in Glaucoma and Diabetic Retinopathy Preclinical Studies at ARVO 2026
Spinogenix presents preclinical data showing Tazbentetol (SPG302) reduces retinal cell loss and preserves visual function in eye disease models at ARVO 2026.
Harmonization of Clinical Trial Regulations: PMDA, TGA & CDSCO Compared
This article compares the clinical trial regulations of PMDA, TGA, and CDSCO, focusing on their impact on drug development and patient safety.
ANVISA Regulatory Changes: Impact on Fast-Track Approvals for Oncology Drugs
This article examines how recent ANVISA regulatory changes affect the fast-track approval process for oncology drugs, enhancing patient access to treatments.
Phathom Pharmaceuticals VOQUEZNA Sales Surge 104% in Q1 2026, Company Maintains Profitability Guidance
Phathom Pharmaceuticals reports $58.3M Q1 revenue from VOQUEZNA, up 104% year-over-year, with 1.35M prescriptions filled and profitability expected Q3 2026.
Aquestive Therapeutics Faces Securities Fraud Lawsuit Despite Anaphylm FDA Review Progress
Aquestive Therapeutics hit with class action lawsuit alleging misleading investor communications about Anaphylm sublingual film FDA approval timeline.
Antibody-Drug Conjugates in Breast Cancer: Enhertu vs. Trodelvy in EU Market
This article compares Enhertu and Trodelvy, two leading antibody-drug conjugates, in their effectiveness for breast cancer treatment in the EU market.
IgA Nephropathy Market to Reach New Heights by 2036 as Novartis Zigakibart and Novel Immunotherapies Drive Growth
IgA nephropathy market expansion driven by Novartis Zigakibart, Roche Sefaxersen, and emerging immunotherapies through 2036 with improved patient outcomes.
Regeneron Q1 2026 Earnings: Dupixent Sales Surge 33% to $4.9B, EYLEA HD Shows Strong Growth
Regeneron reports 19% revenue growth to $3.6B in Q1 2026, driven by Dupixent's 33% sales increase to $4.9B and EYLEA HD's 52% growth to $468M.
Sprout Pharmaceuticals Addyi (Flibanserin) Maker Named Top 10 Most Influential Health Company by TIME 2026
Sprout Pharmaceuticals, maker of Addyi (flibanserin), joins TIME's 10 most influential health companies of 2026 following FDA approval expansion and growth.
CAR-T Therapy Clinical Trials: Insights from ASCO 2026 and FDA Approval Implications
Discover the latest insights on CAR-T therapy from ASCO 2026 and understand the potential implications of FDA approval for innovative cancer treatments.
Bayer Presents 13 Stroke Research Abstracts at ESOC 2026, Including Asundexian Phase III Trial Data
Bayer showcases 13 stroke research abstracts at ESOC 2026, featuring late-breaking Phase III OCEANIC-STROKE trial analyses of Asundexian for stroke prevention.
Pfizer's ELREXFIO Shows Significant Progression-Free Survival Improvement in Multiple Myeloma Phase 3 Trial
Pfizer's ELREXFIO meets primary endpoint in MagnetisMM-5 Phase 3 trial, showing statistically significant progression-free survival improvement for relapsed multiple myeloma patients.
FDA Accelerated Approvals Oncology: 2026 Review of Benefit-Risk and Confirmatory Trials
This article reviews the FDA's Accelerated Approvals in Oncology, highlighting the benefit-risk balance and the importance of confirmatory trials for cancer treatments.
FDA's New AI Validation Framework in Oncology Drug Development
The FDA's new AI validation framework aims to streamline oncology drug development, ensuring more effective cancer therapies through advanced technology.
Intellia Therapeutics Submits FDA Application for Lonvo-Z, First CRISPR Gene Therapy for Hereditary Angioedema
Intellia initiates rolling BLA submission for lonvo-z, a potential one-time CRISPR treatment for hereditary angioedema, marking a breakthrough in gene therapy.
Apollomics Advances Vebreltinib c-MET Inhibitor with Phase 2/3 IND Submission for NSCLC Treatment
Apollomics reports clinical progress for vebreltinib c-MET inhibitor, with over 600 patients dosed and Phase 2/3 IND submission planned for NSCLC combination therapy.
FDA Approves Johnson & Johnson's CAPLYTA (Lumateperone) sNDA for Schizophrenia Relapse Prevention
FDA approves CAPLYTA supplemental application showing 63% relapse risk reduction in schizophrenia patients with 84% remaining relapse-free over six months.
AI Drug Discovery Patent Rankings 2025: Deep EigenMatics Leads Globally
Deep EigenMatics has topped the 2025 AI drug discovery patent rankings, outpacing major pharma globally. Discover how AI is reshaping pharmaceutical innovation.
Ascletis Completes Enrollment for ASC30 Oral GLP-1 Diabetes Drug Phase II Trial
Ascletis Pharma completes enrollment in Phase II trial of ASC30, an oral GLP-1 receptor agonist for diabetes treatment, with results expected Q3 2026.
Ascletis Completes Enrollment in Phase II Trial of ASC30 Oral GLP-1 Diabetes Drug
Ascletis Pharma completes enrollment of 100 patients in Phase II trial of ASC30, an oral GLP-1 receptor agonist for diabetes treatment, with results expected Q3 2026.
Frequently asked questions
Who writes NovaPharmaNews articles?
Each story is attributed to a named editor or analyst with a public author profile. Profiles list credentials, coverage focus, and every published article so readers and AI systems can verify expertise and trace claims to a accountable journalist.
How do I find more coverage from this author?
Scroll to the article archive on this page, or use the topic chips linked from the author’s specializations. The regional authors directory lists every active contributor in this edition.
How does author coverage connect to companies and pipeline data?
Articles link to company profiles, drug INN pages, clinical trials, and pipeline programs when entities are tagged. Use the intelligence spokes on each story or browse topic hubs from the author’s beat.